Brain Tumor, Primary Clinical Trial
Official title:
Assessing Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain resting state networks following radiation therapy using functional imaging. The hypothesis is that radiation therapy leads to dose-dependent alterations in functional connectivity in the networks associated with higher level cognition, ultimately leading to cognitive decline.
Status | Not yet recruiting |
Enrollment | 16 |
Est. completion date | June 30, 2027 |
Est. primary completion date | June 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 21 Years |
Eligibility | Inclusion Criteria: - Between 8 and 21 years of age, inclusive - Newly diagnosed primary brain tumor of any location and any histology that will be treated with proton radiation therapy - Life expectancy of at least one year - Able to understand and willing to consent or assent to the research proposed (or that of a legally authorized representative, if applicable), along with consent of legal guardian(s) if applicable Exclusion Criteria: - Presence of visual impairment to an extent that the patient is unable to complete the computer testing - Contraindication to MRI scan (i.e. due to cardiac pacemaker) - Presence of programmable shunt or dental braces - Requires sedation for MRI scans |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine/Saint Louis Children's Hospital | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | The Foundation for Barnes-Jewish Hospital, United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiation induced effects on functional brain resting state connectivity | The investigators will compare resting state maps of each patient pre- and post-radiation therapy. The investigators will evaluate changes in the resting state architecture and compare to the average results that would be expected from a patient in the same age and sex. | Through 1 year follow-up | |
Primary | Baseline characteristics of functional network architecture | The investigators will assess the unique architecture of brain networks at diagnosis and how significantly this architecture diverges from average healthy controls. | At baseline (day 1) | |
Primary | Change in characteristics of functional network architecture | The investigators will assess brain system segregation which is measure of the connection and disconnection between different brain networks. These will be compared within individuals and compared to healthy controls. | Baseline and 1 year follow-up | |
Secondary | Correlation of radiation dose to changes in cognitive performance and resting state network connectivity | In an exploratory fashion, the investigators will evaluate the dose of radiation received to each resting state network to determine if functional connectivity changes in a dose dependent manner at 1 year. | At 1 year follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
Completed |
NCT03323450 -
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
|
N/A | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Completed |
NCT02599142 -
Comparing Immobilisation Shells in Cranial Radiotherapy
|
N/A | |
Recruiting |
NCT06282562 -
FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
|
N/A | |
Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Completed |
NCT04365647 -
Intra-operative Variation in Size of Brain Tumors After Craniotomy
|
||
Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
Active, not recruiting |
NCT02006407 -
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
|
N/A | |
Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Recruiting |
NCT05775458 -
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
|
||
Terminated |
NCT04901806 -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03373487 -
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
|
N/A | |
Not yet recruiting |
NCT06106997 -
Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
|
N/A | |
Recruiting |
NCT05254197 -
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
|
||
Recruiting |
NCT05092802 -
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
|
Phase 2 |